1. Home
  2. Directory
  3. Pennsylvania
  4. Allentown
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1336875939

CATHLEEN MOIRA KEEGAN-PURSELL CRNP
Prescription History 1336875939
Nurse Practitioner - Acute Care in Allentown, PA

NPI Status: Active since July 26, 2022

Contact Information

1243 S CEDAR CREST BLVD STE 2800
ALLENTOWN, PA
ZIP 18103
Phone: (610) 402-3034
Fax: (610) 402-6979

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CATHLEEN MOIRA KEEGAN-PURSELL CRNP, an active Acute Care specialist practicing in Allentown, PA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 96 documented patient claims. Among these therapy options, the most frequently utilized medication is Lantus Solostar, which accounts for 41 claims alone.

Medication Index

Basaglar Kwikpen U-100

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 26.6
Days Supply 788
PA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills47.6
Peer Average Days Supply1,279
Conservative Utilization

This provider writes prescriptions for this formulation 46.7% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,423.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$463.99

State Avg Cost Per Claim

$382.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Lantus Solostar

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 41
30-Day Fills 85.5
Days Supply 2,563
PA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills74.7
Peer Average Days Supply2,103
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,272.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$470.05

State Avg Cost Per Claim

$552.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Metformin Hcl Er

Generic Formulation: Metformin HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 34.0
Days Supply 1,005
PA State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills124.6
Peer Average Days Supply3,702
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.9% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $218.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.25

State Avg Cost Per Claim

$13.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)

Therapeutic Applications

Metformin is used with a proper diet and exercise program and possibly with other medications to control high blood sugar. It is used in patients with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Metformin works by helping to restore your body's proper response to the insulin you naturally produce. It also decreases the amount of sugar that your liver makes and that your stomach/intestines absorb.

Nano 2nd Gen Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 41.3
Days Supply 1,215
PA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills64.9
Peer Average Days Supply1,918
Conservative Utilization

This provider writes prescriptions for this formulation 48.3% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $881.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.74

State Avg Cost Per Claim

$93.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Novolog Flexpen

Generic Formulation: Insulin AspartSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 19.7
Days Supply 543
PA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills62.5
Peer Average Days Supply1,729
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.6% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,325.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$610.46

State Avg Cost Per Claim

$898.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.

Therapeutic Applications

Insulin aspart is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin aspart is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin aspart starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CATHLEEN MOIRA KEEGAN-PURSELL CRNP provides transparency into local medical care patterns within Allentown, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Acute Care** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.